Benchmark analyst Robert Wasserman downgraded Codexis to Hold from Buy with no price target. The firm cites negative quarterly earnings comparisons and the extended period of time before the company’s long-range projects mature and begin to create more positive growth metrics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDXS:
- Codexis Announces New Employment Inducement Grants
- Codexis Publishes FY2023 Sustainability Disclosures
- CDXS Earnings this Week: How Will it Perform?
- Codexis to Report Second Quarter 2024 Financial Results on August 8
- Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets